Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EYES

Second Sight Medical Products (EYES) Stock Price, News & Analysis

Second Sight Medical Products logo

About Second Sight Medical Products Stock (NASDAQ:EYES)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$4.11
$13.05
52-Week Range
N/A
Volume
36,800 shs
Average Volume
132,982 shs
Market Capitalization
$54.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

EYES Stock News Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Q3 2024 GeneDx Holdings Corp Earnings Call
See More Headlines

EYES Stock Analysis - Frequently Asked Questions

Second Sight Medical Products, Inc. (NASDAQ:EYES) released its quarterly earnings data on Monday, June, 29th. The medical device company reported ($1.71) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by $0.48.

Second Sight Medical Products shares reverse split before market open on Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Second Sight Medical Products (EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Shopify (SHOP).

Company Calendar

Last Earnings
6/29/2020
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:EYES
Employees
15
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.38 million
Price / Cash Flow
N/A
Book Value
$4.80 per share
Price / Book
N/A

Miscellaneous

Free Float
6,935,000
Market Cap
$54.38 million
Optionable
Optionable
Beta
2.55

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:EYES) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners